

One of it's kind Case Simulation with self Assesment based Learning Module

Module 1 starts from Sun, 19<sup>th</sup> Dec, 2021

Module 2 starts from Sun, 23<sup>rd</sup> Jan, 2022

Module 3 starts from Sun, 13<sup>th</sup> Feb, 2022

Module 4 starts from Sun, 6<sup>th</sup> Mar, 2022

1

Every 75 Mins. Module will be active for 30 days.

8

Participants can attend the module at their convenient time

2



Supported by



Click on the link below for registration

Conceived and Managed by



3

https://www.onconxt.com/stepp



One of it's kind Case Simulation with self Assesment based Learning Module

Module 1 starts from Sun, 19<sup>th</sup> Dec, 2021

Module 2 starts from Sun, 23<sup>rd</sup> Jan, 2022

Module 3 starts from Sun, 13<sup>th</sup> Feb, 2022

### Module 4 starts from Sun, 6<sup>th</sup> Mar, 2022

Dear Colleagues,

In recent years, prostate cancer management has become increasingly complex with new surgical techniques, radiotherapy, and the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of the disease.

These case-based dicussions highlight evidence from key trials on next-generation androgen-targeting agents, the role of DNA damage-response mutations, biomarker testing and the potential role of innovative targeted therapy, and advances in immunotherapy for prostate cancer. By providing a "roadmap" to the multiple pathways of prostate cancer management, this program serves as a resource for postgraduate students interested in the present and future applications of new science inpatient care.

Upon completion of this activity, participants should be better able to:

- Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor, patient, and treatment-related factors
- Discuss newer advances in surgical and radiotherapy techniques.
- Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers
- Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp





## **Expert Faculty**



**Dr. Jagdeesh N Kulkarni** Director Minimal Invasive & Robotic Surgery, Prof & Head, Dept of GU/GYN Oncology, ACI - Cumballa Hills Hospital, Mumbai



**Dr. Tejinder Singh** Sr. Consultant Medical Oncologist, Apollo Hospitals, Mumbai



**Dr. Vivek Venkat** Sr. Consultant - Urology & Robotic Urology Nanavati Max Super Speciality Hospital Mumbai



**Dr. Santosh Waigankar** Consultant, Uro-Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai



**Dr. Kaustav Talapatra** Director, Radiation Oncologist, Nanavati Max Super Speciality Hospital Mumbai






#### **Dr. G.V.K. Reddy** Sr. Consultant Medical Oncologist, Yashoda Hospital, Hyderabad

#### **Dr. Adwaita Gore** Associate Director Medical Oncology Nanavati Max Super Speciality Hospital Mumbai

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp





One of it's kind Case Simulation with self Assesment based Learning Module

### Module 2: Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

### Start date: 23<sup>rd</sup> Jan 2022 | End date: 23<sup>rd</sup> Feb 2022

Each 75 minutes Module will be active for 30 days. Participants can attend the Module at their convenient time

TIN	<b>IE</b>	TOPIC	
7:00 -	7:30 pm	Recent Advances in the Therapeutic Management of Metastatic Hormone Sensitive Prostate Cancer	
7:30 -	7:45 pm	Audience Participation in Case Simulation	
7:45 - 8:15 pm		Case Base Discussion (mHSPC)	
		plete Module 1: Metastatic Hormone ostate Cancer (mHSPC)	
1	Recent Advances in the Therapeutic Management of Metastatic Hormone Sensitive Prostate Cancer (Uro-Oncologist Perspective)		
2	Recent Advances in the Therapeutic Management of Metastatic Hormone Sensitive Prostate Cancer		



**Participates in case simulations** 

Expert prospective on the case

Self Assesment

**Download Certificate** 

Supported by



3

4

5

6

Click on the link below for registration

https://www.onconxt.com/stepp





One of it's kind Case Simulation with self Assesment based Learning Module

Each 75 minutes Module will be active for 30 days. Participants can attend the Module at their convenient time

TIME	TOPIC
7:00 - 7:30 pm	Understanding the Evolving Treatment Landscape in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
7:30 - 7:45 pm	Audience Participation in Case Simulation
7:45 - 8:15 pm	Case Base Discussion (mCRPC)

#### Module 3 starts on Sun, 13<sup>th</sup> Feb, 2022

#### Module 4 starts on Sun, 6<sup>th</sup> March, 2022

TIME	TOPIC
7:00 - 7:30 pm	Role of Genetic testing in Prostate Cancer
7:30 - 7:45 pm	Audience Participation in Case Simulation
7:45 - 8:15 pm	Case Base Discussion (HRR Mutation)

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp





One of it's kind Case Simulation with self Assesment based Learning Module

Module 1 starts from Sun, 19<sup>th</sup> Dec, 2021

Module 2 starts from Sun, 23<sup>rd</sup> Jan, 2022

Module 3 starts from Sun, 13<sup>th</sup> Feb, 2022

Module 4 starts from Sun, 6<sup>th</sup> Mar, 2022

Each 75 minutes Module will be active for 30 days. Participants can attend the Module at their convenient time

Concept conceived, developed and managed by

**TIVEZZOUTE** <u>Leaders in Streaming</u> Modules

Dr. Jainam Jain

Webinar Manager, River Route Event, Mumbai M: +91 88888 91624 E: rrcg.drjainam@gmail.com

### Requesting you to share this brochure and link with your colleagues and students

Supported by



Click on the link below for registration

Conceived and Managed by



https://www.onconxt.com/stepp